1. A8.1 Tristetraprolin is a novel therapeutic target for rheumatoid arthritis. (13th February 2015) Authors: Ross, EA; Smallie, T; Naylor, AJ; Desanti, GE; Crowe, J; O'Neil, JD; Turner, JD; Yemm, A; Norling, LV; Perlman, H; Verrills, NM; Filer, A; Dean, JL; Buckley, CD; Clark, AR Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis. Issue 4 (9th April 2015) Authors: Yeo, L; Adlard, N; Biehl, M; Juarez, M; Smallie, T; Snow, M; Buckley, C D; Raza, K; Filer, A; Scheel-Toellner, D Journal: Annals of the rheumatic diseases Issue: Volume 75:Issue 4(2016) Page Start: 763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0038 Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells. (15th June 2017) Authors: Maroof, A; Okoye, R; Smallie, T; Baeten, D; Archer, S; Simpson, C; Griffiths, M; Shaw, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression. Issue 3 (5th September 2016) Authors: Ross, E A; Naylor, A J; O'Neil, J D; Crowley, T; Ridley, M L; Crowe, J; Smallie, T; Tang, T J; Turner, J D; Norling, L V; Dominguez, S; Perlman, H; Verrills, N M; Kollias, G; Vitek, M P; Filer, A; Buckley, C D; Dean, J L; Clark, A R Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 3(2017) Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗